Move to topTop
January 30, 2017

On the 20th Anniversary of Pharmapack, Europe's dedicated Pharmaceutical Packaging and Drug Delivery event in Paris - 1 & 2 February 2017, Terumo will showcase their latest development for PLAJEX polymer prefillable syringes. This new container closure system for luer lock syringes is very user friendly and provides patients and healthcare providers with an easy grip twist-off tip cap.

The Threaded Closure (TC) has been specially designed for PLAJEX COP prefillable syringes with an integrated luer lock, combining the user friendly features with a secure connectivity, while maintaining container closure integrity.


A secure and functional luer connectivity for connections in intravascular applications or hypodermic connections is of paramount importance; PLAJEX combines the design features and the robustness of an integral moulded luer lock with dimensional accuracy and functional performance. The luer cone inner bore is also designed with a large inner bore for mitigating connectivity issues with needle-free IV access devices1).

Contact materials are carefully selected to minimize extractables and leachables. PLAJEX polymer, ready to use syringes are steam sterilized to mitigate possible interactions with sensitive biopharmaceuticals.

PLAJEX integral luer lock syringes with Threaded Closure (TC) are available for use with different syringe sizes and will feature in the future expansion of the TERUMO series of PLAJEX polymer prefillable syringe platform.

  • 1)

    Guidance for Industry and FDA Staff: Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4 - Draft Guidance, April, 2013

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.